Open tender · Germany · Pharmaceutical products
Open-House-Biologika-Rabattverträge 2026-03b - Eculizumab (inkl. der Indikation gMG und NMOSD)
In EnglishOpen-house biologics discount agreements 2026-03b - Eculizumab (including the indications gMG and NMOSD)
Techniker Krankenkasse in Germany is inviting bids for “Open-house biologics discount agreements 2026-03b - Eculizumab (including the indications gMG and NMOSD)”. Bids close on 31 August 2027, 23:58 CEST. askTender lists every requirement to qualify and checks whether your company meets them.
The work
Abschluss von Arzneimittelrabattverträgen nach § 130a Abs. 8 SGB V zu dem Wirkstoff Eculizumab (inkl. der Indikation gMG und NMOSD) im Rahmen eines Open-House-Verfahrens.
Key facts
- Procedure
- Contract notice
Before you bid, askTender
Everything else is in your askTender account
askTender has broken this tender down into 4 requirements to qualify (2 on experience, 2 certifications and registrations) and the 1 document a bidder must file.
- What it takes to qualify: every requirement, in the tender’s own words
- Whether your company qualifies: your profile checked against each requirement, showing what you have, what’s missing and how to close the gap
- The documents to file: a checklist, with draft declarations ready to sign
- A bid partner for any requirement you can’t meet alone
- The tender documents, ready to open
- Alerts for new tenders like this one
Public data: TED – Tenders Electronic Daily. © European Union, 1998–2026. Notices reused under Commission Decision 2011/833/EU. · Sources & licences